Evidence map›Paper›PMID 33148127›Full record

SynthesisTechnology in cancer research & treatment

Role of Human Epididymis Protein 4 (HE4) in Determining Survival of Patients With Endometrial Cancer: A Meta-Analysis.

Ying He, Jing Wang, Chun-Xing Ma, Yan-Hua Kang

Abstract readMeta-Analysis
In one paragraph

Synthesis in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ying HeDepartment of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Jing WangDepartment of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Chun-Xing MaDepartment of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Yan-Hua KangDepartment of Gynecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.ORCID 0000-0001-8742-791X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman epididymis protein 4 (HE4) is a novel cancer biomarker. This study evaluates the prognostic role of HE4 in determining the survival of endometrial cancer patients.

methodsLiterature search was conducted in electronic databases (Embase, Ovid, PubMed, Scopus, and Web of Science). Studies were selected if they reported the relationship between HE4 and the survival of endometrial cancer patients. Random-effects meta-analyses were performed to achieve estimates of baseline serum HE4 levels, the 5-year survival with high and low serum HE4 levels/expression, and the hazard ratios (HRs) of the survival between patients with high and low serum HE4 levels.

results9 studies (1404 patients; age 63.1 years [95% confidence interval (CI): 61.2, 64.9]; follow-up 35.9 months [95% CI: 32.2, 39.6]) were included. In these patients, serum HE4 levels were 83.36 picomole/liter (pM) [95% CI: 70.15, 96.56] overall but these were higher in patients with recurrence (108.13 pM [95% CI: 63.09, 153.18] and lower in patients with no recurrence (67.88 pM [95% CI: 65.09, 70.67]). The 5-year overall survival rate was higher in patients with low HE4 levels/expression (86% [95% CI: 79, 92] but lower in patients with high HE4 levels/expression (63% [95% CI: 58, 68]. A pooled HR of survival between patients with high and low serum HE4 levels of 2.25 [95% CI: 1.56, 2.94] indicated shorter survival in patients with high serum HE4 levels.

conclusionHigh HE4 concentrations in patients with endometrial cancer are found to be associated with shorter survival.

Indexed as

Biomarkers, TumorDisease ProgressionEndometrial NeoplasmsFemaleHumansPrognosisProportional Hazards ModelsWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humancancer biomarkerendometrial cancerhuman epididymis protein 4survival

Identifiers

PMID33148127
PMCPMC7653290

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.